EMA — authorised 16 January 2007
- Marketing authorisation holder: Eisai Ltd
- Status: approved
🇪🇺 Banzel in European Union
EMA authorised Banzel on 16 January 2007
Marketing authorisations
EMA — authorised 16 January 2007
- Application: EMEA/H/C/000660
- Marketing authorisation holder: Eisai GmbH
- Local brand name: Inovelon
- Indication: Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.
- Status: approved
Banzel in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in European Union
Frequently asked questions
Is Banzel approved in European Union?
Yes. EMA authorised it on 16 January 2007; EMA authorised it on 16 January 2007.
Who is the marketing authorisation holder for Banzel in European Union?
Eisai Ltd holds the EU marketing authorisation.